Maraviroc, a CCL5/RANTES inhibitor, ameliorated hepatic steatosis in a high-fat diet (HFD)-induced model of NAFLD (108). The gene discussed is CCL5; the disease is metabolic dysfunction-associated steatotic liver disease.